Table 1.

Baseline characteristics of 44 postmenopausal breast cancer survivors after completion of primary therapy and prior to randomization in a dietary supplement intervention

	All Participants (n=44)		Previous Chemotherapya (n=15)		No Chemotherapyb (n=29)
	Mean (SD)	N (%)	Mean (SD)	N (%)	Mean (SD)	N (%)	P-valuec
Demographics
Age (years)	59.5 (8.1)		58.0 (8.6)		60.3 (7.8)		0.37
Race							0.46
White		43 (98%)		15 (100%)		28 (97%)
African American		1 (2%)		0 (0%)		1 (3%)
Body Mass Index (kg/m2)	29.8 (6.2)		30.3 (7.2)		29.4 (5.6)		0.66
Tobacco Use							0.52
Current		1 (2%)		1 (7%)		0 (0%)
Previous		11 (25%)		3 (20%)		8 (28%)
Never		32 (73%)		11 (73%)		21 (72%)
Prior Chronic Conditions
Osteoarthritis		5 (11%)		1 (7%)		4 (14%)	0.65
Fibromyalgia		1 (2%)		0 (0%)		1 (3%)	1.00
Hyperlipidemia		5 (11%)		1 (7%)		4 (14%)	0.65
Hypertension		14 (32%)		5 (33%)		9 (31%)	1.00
Other		28 (64%)		10 (67%)		18 (62%)	1.00
Disease Characteristics
Estrogen Receptor Positive		43 (98%)		14 (93%)		29 (100%)	0.34
Progesterone Receptor Positive		39 (89%)		11 (73%)		28 (97%)	0.04
T-stage d							0.20
T1a		6 (14%)		2 (13%)		4 (14%)
T1b		25 (57%)		6 (40%)		19 (66%)
T2		11 (25%)		6 (40%)		5 (17%)
T3		2 (5%)		1 (7%)		1 (3%)
T4		0 (0%)		0 (0%)		0 (0%)
Her2Neu e							0.52
Positive		2 (5%)		1 (7%)		1 (3%)
Negative		42 (95%)		14 (93%)		28 (97%)
Cancer Treatment
Radiation		26 (59%)		7 (47%)		19 (66%)	0.33
Chemotherapy		15 (34%)		15 (100%)		0 (0%)	--
Functional Assessment of Cancer Therapy f
FACT-General g h	91.6 (11.0)		95.4 (8.0)		89.6 (11.9)		0.10
-Physical Well Being	24.9 (2.8)		24.9 (2.2)		24.9 (3.1)		0.94
-Social Well Being	24.5 (4.1)		26.4 (2.0)		23.5 (4.5)		0.02
-Emotional Well Being	20.1 (2.8)		20.4 (3.0)		20.0 (2.7)		0.63
-Functional Well Being	22.1 (5.4)		23.7 (3.7)		21.3 (6.0)		0.17
Breast Cancer Subscale	26.5 (4.0)		25.8 (4.3)		26.9 (3.8)		0.39
FACT-Breast g i	118.1 (13.6)		121.2 (11.4)		116.5 (14.5)		0.28
Endocrine Symptom Subscale	63.8 (8.1)		63.5 (7.4)		64.0 (8.5)		0.88
FACT-ES g j	181.9 (19.4)		184.7 (17.3)		180.4 (20.5)		0.49
Stanford Health Assessment Questionnaire
SHAQ k	0.13 (0.34)		0.06 (0.12)		0.16 (0.41)		0.34
SHAQ > 0 k l		11 (25%)		3 (19%)		8 (29%)	0.72
Serum inflammatory cytokines
Interleukin-6 (pg/mL) m	1.8 (1.2)	N=41	2.4 (1.6)	N=15	1.5 (0.88)	N=26	0.03
TNFR-2 (pg/mL) n	6374 (1507)	N=42	6853 (1427)	N=15	6108 (1510)	N=27	0.13
Interleukin-17 (pg/mL) m	0.52 (0.45)	N=41	0.57 (0.49)	N=14	0.49 (0.43)	N=27	0.26

^aParticipants with history of chemotherapy prior to study enrollment

^bParticipants without history of chemotherapy prior to study enrollment

^cP-values from two-sample t-tests and Fisher’s exact tests comparing previous chemo to no chemo

^dT-Stage is a classification of primary tumor size. A tumor that is larger and/or has grown into nearby tissues receives a higher number.

^eHer2Neu (human epidermal growth factor receptor 2) positive cancers grow faster and are more likely to spread; patients can receive specific medication to target these cancers.

^fFor all Functional Assessment of Cancer Therapy scales, higher score = higher quality of life

^gFACT, Functional Assessment of Cancer Therapy

^hFACT-General includes all well-being subscales

ⁱFACT-Breast = FACT General + Breast Cancer Subscale

^jFACT-ES (Breast with Endocrine Subscale) = FACT General + Breast Cancer Subscale + Endocrine Symptom Subscale

^kSHAQ, Stanford Health Assessment Questionnaire

^lSHAQ >0 = some reported disability

^mT-tests performed on log transformed data for Interleukin-6 and Interleukin-17

ⁿTNFR-2, Tumor necrosis factor alpha receptor 2